Antioxidant N-acetylcysteine was intended to inhibit NFκB in the tumor microenvironment in patients with persistent or recurrent high-grade ovarian, primary peritoneal, or fallopian tube cancer in clinical trial NCT02569957, but the study was halted prematurely due to slow accrual. The gene discussed is NFKB1; the disease is neoplasm.